ClinicalTrials.gg
RecruitingNCT07614490Updated May 29, 2026

Clinical Study to Collect and Analyze Dental Plaque and Oral Health Measures in a Population With High Plaque/Low Gingivitis and High Plaque/High Gingivitis

A Phase 4 interventional study of sodium monofluorophosphate toothpaste in Gingivitis and Plaque, sponsored by Colgate Palmolive. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by Colgate Palmolive · Phase 4, Interventional, and Basic science

How we know · 4 judgments

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 44 studies in Gingivitis by Colgate Palmolive — 8 open to participants now, 9 under way, 5 of them phase 3. Gingivitis · Colgate Palmolive.

Planned enrollment
16th of 44
100 · median 94
Started
2026
with 11 others
Phase 4
12 of 44
4 open now
Registered
38th of 44
by date

Among the 44 studies in Gingivitis by Colgate Palmolive, this one is the 16th largest by planned enrollment, is one of 12 that started in 2026, is one of 12 in phase 4, and was the 38th registered.

Gingivitis

635 studies on the registry are indexed under Gingivitis; 109 are open to participants now.

Browse Gingivitis studies →

Open to participants now

8 of the 44 studies in Gingivitis by Colgate Palmolive are open now, in 5 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Who these studies take

Of the 54 Gingivitis studies recruiting now, 16 (30%) set no upper age limit and 36 (67%) stop at 75 or younger; 11 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Gingivitis by Colgate Palmolive, or all of them as a file.
02

Study summary

The objective of this clinical research study is to collect and analyze plaque and oral health measures in a population with high plaque/low gingivitis and high plaque/high gingivitis

Read the detailed description

This study is a single-arm clinical trial. Up to one hundred (100) male and female subjects who meet the inclusion/exclusion criteria will be enrolled in order to complete the study with eighty (80) subjects. Subjects will undergo oral examinations, gingival crevicular fluid collection, saliva collection, plaque collection, and will complete questionnaires. All subjects will all be supplied with a study toothbrush and toothpaste.

03

Conditions studied

  • Gingivitis
  • Plaque

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female volunteers at least 18 years of age and in general good health.
  • Willing and able to understand and sign the form.
  • Must have a whole mouth mean TPI score ≥ 3.25
  • N=40 must have moderate-severe gingivitis (Whole Mouth Mean MGI≥2.5 or percent bleeding sites based on EBI ≥20%) and N=40 must have mild gingivitis (Whole Mouth Mean MGI≤2.5 and percent bleeding sites based on EBI\<20%)
  • Must have at least two areas in the mouth with high plaque/low inflammation and two areas with high plaque/high inflammation
  • Be willing to conform to the study protocol and procedures.
  • Minimum of 20 natural teeth with scorable facial and lingual surfaces

Exclusion criteria

Exclusion Criteria:

  • Medical condition which requires premedication prior to dental visits/procedure.
  • Known history of allergy to personal care/consumer products or their ingredients, relevant to any ingredients in the test products as determined by the study examiner.
  • Active disease of the hard oral tissues.
  • Significant oral soft tissue pathology, excluding plaque-induced gingivitis.
  • Subjects with fixed or removable orthodontic appliances or removable partial dentures.
  • Dental prophylaxis within 30 days prior to study start.
  • Use of antibiotics, antimicrobial drugs, anti-inflammatory drugs, or anticoagulant therapies within 30 days prior to study start.
  • Use of chemotherapeutic oral care products within two weeks prior to study start.
  • Participation in any other clinical study within 30 days prior to enrollment into this study.
  • Subjects who must receive dental treatment during the study dates.
  • individuals (, AIDS, immunosuppressive drug therapy).
  • Use of smokeless tobacco, vaping, or e-cigarettes or suspected substance abuse.
  • Current smokers (if former smoker, should have stopped at least 1 month prior to Visit 1)
  • Pregnant or lactating subjects, or subjects planning to become pregnant during the course of the study.
  • Medical condition which prohibits not eating/drinking or chewing gum for four (4) hours prior to your scheduled visits;
  • Subjects who have an infectious disease and/or other blood borne diseases (Hepatitis series, HIV, tuberculosis).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Other
    Brushing with sodium fluoride toothpaste

    Drug: sodium monofluorophosphate toothpaste

Interventions

  • Drugsodium monofluorophosphate toothpaste

    All subjects will receive the same treatment for standardization

06

What researchers measure

Primary outcomes

  1. Relative abundance of Streptococcus and Porphyromonas

    Comparative relative abundance of Streptococcus and Porphyromonas in sites with high plaque/low gingivitis and high plaque/high gingivitis at Visit 3

    Time frame: 23-26 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Depends on the inquiry

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Sep 2026, 5 months after the start.

Of 25 phase 4 interventional studies under Gingivitis, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 4. This study's planned 5 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 17, 2026
First posted
May 29, 2026
StartActual
Apr 20, 2026
Primary completionEst.
Sep 30, 2026
CompletionEst.
Oct 15, 2026
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07614490
Lead sponsor
Colgate Palmolive
Responsible party
Sponsor
First posted
May 29, 2026
Start date
Apr 20, 2026
Primary completion
Sep 30, 2026 (estimated)
Completion
Oct 15, 2026 (estimated)
Last update
May 29, 2026

Study contacts

Jeffery Milleman, DDS, MPA
Contact
milleman@salusresearch.us
260-755-1099
Gabriella John, MS
study director · Colgate Palmolive

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion